AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2016
Sep 7, 2016
31289_dirs_2016-09-06_314c1d3d-b135-404a-acac-c9ae5b4b0016.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-09-01
Reporting Person: KOZARICH JOHN W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-09-01 | Common Stock | S | 200.0 | $103.59 | Disposed | 40783 | Direct |
| 2016-09-01 | Common Stock | S | 400.0 | $104.6575 | Disposed | 40383 | Direct |
| 2016-09-01 | Common Stock | S | 866.0 | $105.8231 | Disposed | 39517 | Direct |
| 2016-09-01 | Common Stock | S | 200.0 | $106.865 | Disposed | 39317 | Direct |
Footnotes
F1: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.22 to $103.96, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.29 to $105.17, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.41 to $106.37, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.85 to $106.88, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.